Search Result

Results for "

FER

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Anaplastic lymphoma kinase (ALK) (4) Aurora Kinase (1) Bcr-Abl (1) CaMK (1) CDK (2) Cyclin G-associated Kinase (GAK) (1) FAK (1) Ferroptosis (4) Fungal (1) LIM Kinase (LIMK) (2) MAP4K (1) MAPKAPK2 (MK2) (1) PROTACs (4) Salt-inducible Kinase (SIK) (2) Small Interfering RNA (siRNA) (2) ULK (2) Wee1 (1)
By Research Areas:	Cancer (9) Neurological Disease (1)

Inhibitors & Agonists

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

Ferrostatin-1 Maximum Cited Publications 523 Publications Verification FER-1	Ferroptosis Fungal	Cancer
Ferrostatin-1 (Fer-1), a potent and selective ferroptosis inhibitor, suppresses Erastin-induced ferroptosis in HT-1080 cells (EC₅₀=60 nM). Ferrostatin-1, a synthetic antioxidant, acts via a reductive mechanism to prevent damage to membrane lipids and thereby inhibits cell death. Ferrostatin-1 exhibits antifungal activity .

E260 1 Publications Verification	Others	Cancer
E260 is a *Fer/FerT* kinase inhibitor.

SRS11-92	Ferroptosis	Neurological Disease Cancer
SRS11-92, a Ferrostatin-1 (Fer-1) analogue, is a potent ferroptosis inhibitor. SRS11-92 inhibits ferroptotic cell death induced by Erastin in HT-1080 human fibrosarcoma cells (EC₅₀=6 nM) .

FER Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FER Human Pre-designed siRNA Set A contains three designed siRNAs for FER gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FER Human Pre-designed siRNA Set A FER Human Pre-designed siRNA Set A

FER1L6 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
FER1L6 Human Pre-designed siRNA Set A contains three designed siRNAs for FER1L6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

FER1L6 Human Pre-designed siRNA Set A FER1L6 Human Pre-designed siRNA Set A

DS21360717	Others	Cancer
DS21360717 is a potent and orally active *FER* tyrosine kinase inhibitor, with an IC₅₀ of 0.49 nM. Anti-cancer activity .

Ifebemtinib BI-853520; IN-10018	FAK	Cancer
Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC₅₀=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC₅₀s of 900 nM and 1040 nM, respectively .

TL13-22	Anaplastic lymphoma kinase (ALK)	Cancer
TL13-22 is a negative control for TL13-12 (HY-122582) and a potent ALK inhibitor with an IC₅₀ of 0.54 nM. TL13-22 does not degrade ALK in cells .

TL13-110	Anaplastic lymphoma kinase (ALK)	Cancer
TL13-110 is a negative control for TL13-112 (HY-123919) and a potent ALK inhibitor with an IC₅₀ of 0.34 nM. TL13-110 does not degrade ALK in cells .

TL13-112 1 Publications Verification	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-112 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.14 nM. TL13-112 also prompts the degradation of additional kinases including Aurora A, *FER, PTK2* and RPS6KA1 with IC₅₀ values of 8550 nM, 42.4 nM, 25.4 nM, and 677 nM, respectively. TL13-112 is comprised of the conjugation of Ceritinib (HY-15656) and the Cereblon ligand of Pomalidomide (HY-10984) .

TL13-12	PROTACs Anaplastic lymphoma kinase (ALK)	Cancer
TL13-12 is a potent and selective ALK-PROTAC degrader and inhibits ALK activity with an IC₅₀ value of 0.69 nM. TL13-12 also prompts the degradation of additional kinases including Aurora A, *FER, PTK2, and RPS6KA1* with IC₅₀ values of 13.5 nM, 5.74 nM, 18.4 nM, and 65 nM, respectively. TL13-12 is comprised of the conjugation of TAE684 (HY-10192) and the Cereblon ligand of Pomalidomide (HY-10984) .

DB0614	PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) ULK Wee1 LIM Kinase (LIMK)	Others
DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity .

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Others
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .

Cat. No.	Compare	Product Name	Species	Source

	FER Protein, Human (sf9, GST) FER; FER (fps/fes related) tyrosine kinase; tyrosine-protein kinase FER; phosphoprotein NCP94; PPP1R74; protein phosphatase 1; regulatory subunit 74; TYK3; p94-FER; tyrosine kinase 3; proto-oncogene c-FER; feline encephalitis virus-related kinase FER; protein phosphatase 1, regulatory subunit 74; fujinami poultry sarcoma/Feline sarcoma-related protein FER; FERT	Human	Sf9 insect cells


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Name
Email *

	Sorry, but the email address you supplied was invalid.